Transgenic Tau Mouse Models – Tau[P301S] Mouse Model

Although both InnoSer’s mouse model Tau[P301S] line (referred to as the h.TauP301S model across scientific literature) and the widely available Tau[P301S] PS19 line are single-transgenic tauopathy models expressing the P301S mutant form of human MAPT, important differences exist across model construct, phenotype, and study timelines. 

At the construct level, PS19 mice express mutant human tau under the prion protein (PrP) promoter, which drives high neuronal expression and results in a rapidly progressing tauopathy. In contrast, InnoSer’s Tau[P301S] mice express human tau under the mouse Thy1 promoter, leading to a more controlled and regionally relevant neuronal tau expression profile. 

With respect to disease development, although tau pathology has been reported at earlier ages in PS19 mice (ca 6 months of age), robust and reproducible tau pathology is most reliably observed at approximately 8–9 months of age. However, an extensive study comparing PS19 and Tau[P301S] phenotypes has highlighted variability in pathology at 8 months of age in the PS19 line, reporting that some mice had 3-fold more tau prions compared to others (Woerman et al., 2017). In turn, this variability may have important implications for study design, choice of endpoints readouts, statistical power, and interpretation of efficacy outcomes.  

Efficacy studies in PS19 mice are typically initiated around 6 months of age and run until 9 months of age. In contrast to the Tau PS19 line, InnoSer’s Tau[P301S] mice rapidly develop tau-associated pathology and can be used for preclinical efficacy studies from approximately 2.5 to 5.5 months of age, enabling faster study initiation due to minimal waiting time for animals to reach the appropriate disease stage. In agreement, the relative frequency of mouse models and treatment start ages are also illustrated in Figure 3 of a recent, comprehensive 20-year tauopathy mouse model review written by Langness and colleagues (2025).  

Despite known limitations, the PS19 line remains the most widely used Tau[P301S] line to evaluate novel Tau-targeting therapeutics, accounting for approximately 30% of preclinical tauopathy studies, compared with roughly 8% for Tau[P301S], as highlighted in the review of Langness et al., 2025. The continued popularity of the Tau PS19 line across preclinical efficacy studies can be owed to its historical adoption, as well as the model being one of the earliest established models of human tauopathy. Many researchers continue to choose to work with this model to maintain continuity with prior studies and/or internal benchmarks.  

While InnoSer’s Tau[P301S] line offers less variability and faster study timelines, we also routinely carry out preclinical efficacy studies in the PS19 line when scientific objectives, translational strategy, or legacy data require it.  

Our team works closely with you to select the most appropriate Tau mouse model based on the specific disease mechanisms, endpoints, and patient populations of interest. 

Reach out to our expert team to inquire which Tau mouse model is the most suitable for your research.  

Both Tau[P301S] (originally described by Allen et al., 2002) and Tau[P301L] (originally described by Terwell et al., 2005) mouse models feature pathogenic mutations in the human MAPT gene, which are associated with various forms of familial frontotemporal lobar degeneration (FTLD). However, they differ markedly in the development of tau disease pathophysiology and thus, experimental utility.  

Following InnoSer’s Tau[P301S] in-depth characterization studies, we detect early and robust tau-associated pathology, including pronounced tau hyperphosphorylation, accumulation of insoluble tau species, starting already at 3 months of age, insoluble pTau at 4.5 months of age, and progressing rapidly until 6 months of age, when robust tau pathology is present. In this model, tau pathology is widespread across the brain, including the cortex, hippocampus, and brainstem, and is accompanied by associated neuroinflammation and neuronal loss in the spinal cord (van Olst et al., 2020). Robust motor deficits confirmed by InnoSer’s team at 5 months of age, and cognitive deficits in Morris water maze performance and age-dependent hippocampal LTP impairment emerging from ~3.5 months of age. This rapid and consistent phenotype enables you to perform reproducible preclinical efficacy and target-engagement studies with short in vivo study timelines.  

In contrast, in the Tau[P301L] model evaluated by InnoSer, consistent with scientific literature, tau pathology develops more gradually, with more variable and later onset of neurofibrillary tangle–like pathology occurring around 7-8 months of age. In this model, tau pathology is limited to the brain stem (and spinal cord) with a decreasing extent in the midbrain and cerebral cortex. Although Tau[P301L] mice show progressive, age-dependent deficits in motor function (beam walk, clasping phenotype), these are present starting from 7 months of age, with robust, detectable deficits occurring at 9 months of age.   

This slower disease progression makes the Tau[P301L] model more suitable for longitudinal studies focused on disease evolution, chronic treatment paradigms, and mechanisms underlying progressive tau aggregation.  

Taken together, InnoSer generally recommends running efficacy studies in Tau[P301S] model due to its rapid, reproducible tau pathology and behavioral phenotype, helping you obtain quick preclinical decisions. Tau[P301L] model may be better suited for studies requiring extended observation of tauopathy progression. 

Reach out to InnoSer’s expert team to discuss which Tau mouse model is the most suitable for your research.  

Although young (~3.5 months old) homozygous Tau[P301S] mice do show early signs of cognitive deficits in the Morris water maze test and Cogntion Wall, in InnoSer’s experience, the mice develop aggressive early-onset motor impairments that interfere with reliable assessment of cognition using standard behavioral tests at older ages.  

As a result, classical cognitive testing becomes technically challenging as motor deficits precede and/or overlap the emergence of cognitive dysfunction in Tau[P301S] mice. 

As an alternative in the Tau[P301S] model, synaptic and memory-related deficits can be evaluated using electrophysiological readouts using ex vivo brain slices, such as hippocampal long-term potentiation (LTP), which provide sensitive and motor-independent measures of synaptic plasticity that can serve as a proxy measure for memory deficits in Tau[P301S] mice. Indeed, InnoSer’s internal validation datasets show that this mouse model shows significant deficits compared to WT littermates in synaptic plasticity in the CA1 region using hippocampal ex vivo brain slices obtained from 3-month-old mice.  

Reach out to InnoSer’s expert team to inquire about performing LTP ex vivo experiments using hippocampal brain slices from the Tau[P301S] mouse model.

Generally speaking, InnoSer’s Tau[P301S] mouse model is suitable to evaluate a wide spectrum of Tau-targeting therapeutics currently in the discovery and preclinical stages (for review of all therapeutic Tau approaches, we refer you to Langness et al., 2025). 

These include: active vaccine immunization targeting tau protein, compounds (small molecules, ASOs) targeting primary disease-associated mechanisms, including microtubule stabilization, tau aggregation, tau isoform imbalance, tau propagation, tau reduction.  

Compounds (small molecules, ASOs) targeting secondary disease-associated mechanisms such as energy metabolism, oxidative stress, proteostasis network, cellular senescence, immune response, and lipid metabolism – to name a few – can be evaluated in this model as well.  

Reach out to InnoSer’s team to confirm whether the Tau[P301S] mouse model is the most suitable for your research.

Yes, published research has shown that disease modification has been demonstrated in the Tau[P301S] mouse model in preclinical studies targeting key tau-driven pathological mechanisms.  

Notably, treatment with anti-Tau antibodies has been shown to reduce Tau pathology and slow disease progression (Chai et al., 2011). In addition, autophagy-enhancing approaches, such as the mTOR inhibitor rapamycin, have demonstrated efficacy by reducing pathological Tau accumulation and improving disease-associated phenotypes (Ozcelik et al., 2013). 

Together, these findings support the translational relevance of the Tau[P301S] mouse model for evaluating disease-modifying therapies aimed at Tau aggregation, clearance, and downstream neurodegenerative processes. 

Yes, as a preclinical neurodegeneration CRO, InnoSer maintains access to established breeding cohorts of the Tau[P301S] mouse model, enabling rapid study initiation depending on the required animal age and genotype.  

Our proactive colony planning ensures that your preclinical efficacy studies can be launched with minimal lead time.  

Contact our team to confirm current availability and obtain study timelines for your Tau-targeting therapeutic still today.